{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:04:37Z","timestamp":1790521477803,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M652805"],"award-info":[{"award-number":["2019M652805"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31900880"],"award-info":[{"award-number":["31900880"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570537"],"award-info":[{"award-number":["81570537"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974074"],"award-info":[{"award-number":["81974074"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bbrc.2020.10.039","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T18:41:40Z","timestamp":1603737700000},"page":"1047-1052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor"],"prefix":"10.1016","volume":"534","author":[{"given":"Longying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hudie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.10.039_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10853-2","article-title":"Molecular tuning of farnesoid X receptor partial agonism","volume":"10","author":"Merk","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.039_bib2","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/pro.3496","article-title":"The nuclear receptor superfamily: a structural perspective","volume":"27","author":"Weikum","year":"2018","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbrc.2020.10.039_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbrc.2020.10.039_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12072-015-9656-7","article-title":"Bile acids: emerging role in management of liver diseases","volume":"9","author":"Asgharpour","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bbrc.2020.10.039_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10713","article-title":"Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis","volume":"7","author":"Gomez-Ospina","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.039_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.bbrc.2020.10.039_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-015-0500-2","article-title":"FXR agonists as therapeutic agents for non-alcoholic fatty liver disease","volume":"17","author":"Carr","year":"2015","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.bbrc.2020.10.039_bib8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1080\/14656566.2016.1218471","article-title":"Obeticholic acid for the treatment of primary biliary cholangitis","volume":"17","author":"Ali","year":"2016","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.bbrc.2020.10.039_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2020.10.039_bib10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2020.10.039_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrc.2020.10.039_bib12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic acid: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2020.10.039_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic acid: an update of its pharmacological activities in liver disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbrc.2020.10.039_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cct.2019.105889","article-title":"A\u00a0randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.bbrc.2020.10.039_bib15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/apt.15967","article-title":"Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea","volume":"52","author":"Camilleri","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2020.10.039_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jceh.2013.10.005","article-title":"Progressive familial intrahepatic cholestasis","volume":"4","author":"Srivastava","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.bbrc.2020.10.039_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2020.10.039_bib18","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bbrc.2020.10.039_bib19","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2020.10.039_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2020.10.039_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.bbrc.2020.10.039_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2019.11.192","article-title":"Structural basis of NR4A1 bound to the human pituitary proopiomelanocortin gene promoter","volume":"523","author":"Jiang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2020.10.039_bib23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1097-2765(03)00112-6","article-title":"Structural basis for bile acid binding and activation of the nuclear receptor FXR","volume":"11","author":"Mi","year":"2003","journal-title":"Mol. Cell."},{"key":"10.1016\/j.bbrc.2020.10.039_bib24","doi-asserted-by":"crossref","first-page":"19795","DOI":"10.1074\/jbc.RA119.010730","article-title":"Structural basis of binding of homodimers of the nuclear receptor NR4A2 to selective Nur-responsive DNA elements","volume":"294","author":"Jiang","year":"2019","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2020.10.039_bib25","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1039\/C8CC07546H","article-title":"LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance","volume":"54","author":"Wu","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bbrc.2020.10.039_bib26","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1039\/C9CC02052G","article-title":"Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4","volume":"55","author":"Zhou","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bbrc.2020.10.039_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bbrc.2020.10.039_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymeth.2011.07.005","article-title":"The Phenix software for automated determination of macromolecular structures","volume":"55","author":"Adams","year":"2011","journal-title":"Methods"},{"key":"10.1016\/j.bbrc.2020.10.039_bib29","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1016\/j.bmcl.2008.06.073","article-title":"Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW 4064","volume":"18","author":"Akwabi-Ameyaw","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.bbrc.2020.10.039_bib30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0968-0004(97)01140-7","article-title":"PDBsum: a Web-based database of summaries and analyses of all PDB structures","volume":"22","author":"Laskowski","year":"1997","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbrc.2020.10.039_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/bmb.20987","article-title":"PyMOL mControl: manipulating molecular visualization with mobile devices","volume":"45","author":"Lam","year":"2017","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"10.1016\/j.bbrc.2020.10.039_bib32","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1093\/nar\/gkz077","article-title":"Structural basis for DNA recognition by FOXC2","volume":"47","author":"Chen","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2020.10.039_bib33","article-title":"Structural basis of GPBAR activation and bile acid recognition","volume":"22","author":"Yang","year":"2020","journal-title":"Nature"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20319562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20319562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:11:29Z","timestamp":1778638289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20319562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":33,"alternative-id":["S0006291X20319562"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.039","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}